George Goldsmith has spent most of his life creating companies that help people work across the different boundaries that separate us as individuals and organisations …
Dr. Ekaterina Malievskaia received her medical degree from St.Petersburg Medical…
Lars Christian Wilde is Co-Founder and Chief Operating Officer of COMPASS…
Susan C Stansfield gained her PhD in neuroendocrinology in 1980s and began her career in the…
I have spent my life working with teams of leaders seeking to do extraordinary things. The best of them fight the tendency to accept zero-sum strategies and declare victory. They understand that we can create environments where people suspend disbelief, build trust and chase unlikely combinations of new ideas and technologies.
George's early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science.
His first company, The Human Interface Group – a pioneer in collaborative software – was acquired by Lotus Development. George led the Lotus Institute and created software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership. He eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organization and its International Board of Directors, George founded YPO Networks.
In 2002, George founded Tapestry Networks, an organization committed to improving leadership performance and governance effectiveness in regulated sectors. He currently also serves as Tapestry Networks' non-executive Chairman.
George also serves on the board of directors for AnaBios - a company redefining drug discovery. He and his wife, Ekaterina Malievskaia, MD, live in London.
After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. Following family challenges to access evidence-based and effective mental health care, Ekaterina and her husband George Goldsmith formed COMPASS, a medical research foundation focusing on accelerating access to innovation in mental health and well being, where she leads Research and Development.
I have personally witnessed how devastating the impact of depression can be on a person’s life in my close circle of friends. This friend had the privilege of having been treated with psilocybin and he has been relieved of the debilitating disease ever since. Unfortunately, this treatment is not available to most people in the world and it has yet to be proven to be effective in large scale clinical trials. After having founded and invested in several companies in the past, I recognized that COMPASS offers the opportunity to build something immensely beneficial for our global society. I am excited by the outlook of solving one of humanity’s largest unmet medical needs together with an extremely smart and vision driven team.
Lars is also active as a business angel investor and advisor. In this role Lars helped to successfully build e.g. companies such as Otto Wilde Grillers and Emma & Noah.
Before joining COMPASS, Lars was the founder and CEO of Springlane, the leading German kitchen equipment online retailer and the largest German cooking magazine. Being a hobby chef himself Lars realized that cooking went from being a necessity of every household to being a hobby that an increasingly larger share of the population enjoys spending their free time with. Exploiting this trend, Lars built Springlane from a small two person business into a company that produces its own brands and product ranges, is active in several European countries, runs offline retail stores and raised over 30m EUR in capital from some of the leading European venture capital firms.
Before starting Springlane, Lars worked as an investor at Waterland Private Equity, the world’s best performing private equity fund. Amongst other buy-and-build investments, Lars focused on building the largest European invitro fertilization group VivaNeo. The VivaNeo clinics group combines the knowledge of some of the leading European IVF physicians to provide patients with cutting edge medical solutions.
After finishing his graduate studies, Lars spent some time with Boston Consulting Group in Munich and Sao Paulo.
Lars holds a Master in Finance with distinction from IE Business School in Spain and a Bachelor of Science in Business Administration with distinction from Rotterdam School of Management, Erasmus University in the Netherlands. Lars spent exchange semesters at Westfälische Wilhelms-Universität Münster, Copenhagen Business School and the Ross School of Business at the University of Michigan.
Prior to joining Tapestry Networks, Joe worked as an independent contractor providing CFO services to early stage companies. Prior to that, Joe worked at Goldman Sachs in New York.
Joe holds a bachelor’s degree in engineering from the University of Wisconsin and an MBA from the Kellogg School of Management.
It is so refreshing to work in such a dynamic team with one single agenda; to overcome the barriers in order to benefit patients.
In 1991, Sue joined Quintiles as the Global Project Director leading the development of a reversible inhibitor of monoamine oxidase A (RIMA) towards an NDA in panic disorder and social phobia with line extension outside USA. From there, Sue pursued a career in the Clinical Research Organisation (CRO) industry that spanned 25 years. Subsequently she worked for the top CROs PPD, PRA, Premier Research and inVentiv Health; expanding her remit to encompass additional functions and geographic regions. At Compass Pathways, Sue has combined her scientific experience with her trial execution expertise to lead the clinical trials programme.
My goal is to work on a mission-driven early-stage venture with like-minded people. The mission of COMPASS aligns perfectly with my belief in innovative outcome-based healthcare delivery models, in a therapeutic area with significant unmet medical need. I'm excited to be, together with the whole COMPASS team, on the journey to provide new alternatives to mental health disorders like treatment-resistant depression worldwide.
Before joining COMPASS, John attended the Harvard Business School (HBS) for an MBA. During and after his studies he co-founded a technology company focused on enterprise productivity software. Before HBS, he worked at the Boston Consulting Group (BCG) and specialised in healthcare. He advised global pharmaceutical companies as well as hospital networks across Western Europe and North America. His experience includes R&D strategy, new drug market access strategy, and value-based healthcare outcome measurement.
Before BCG, John graduated from the Massachusetts Institute of Technology (MIT) with bachelors in mechanical engineering and economics with distinction and the University of Cambridge with a masters in Energy Technologies with distinction. An avid traveller, he calls both sides of the Atlantic home.
Sir Alasdair Breckenridge is former Chair of the…
Thomas R. lnsel, M.D. is a psychiatrist and neuroscientist. From 2002-2015, Dr. Insel served…
Professor Guy Goodwin is Senior Research fellow at the University of Oxford, Oxford, UK…
Mike has over 30 years in pharmaceutical industry research including strategic and operational leadership…
Marco is currently VP of Strategy for WebMD and Medscape, the leading online health information sources…
Dr. Rush is Professor Emeritus, Duke-National University of Singapore (Duke-NUS)…
As a regulator I was intrigued by the possible use of a drug with a previously uncertain reputation in a novel situation and how the regulatory hurdles could be overcome. To take a drug from the 1950s and reposition it in modern medicine especially for an unmet medical need presents a series of fascinating challenges.
During his tenure at MHRA, Sir Alasdair served as the first Chair of the Department of Health’s Emerging Science and Bioethics Advisory Committee (ESBAC), an organisation responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council and he worked closely on several programmes of the European Union, the World Health Organisation and the International Union of Pharmacology and as Chair of the Committee on Safety of Medicines.
Prior to MHRA, he was Professor of Clinical Pharmacology at the University of Liverpool and a member, and then Chairman, of local and regional health authorities in the north-west of England, including Chairman of the North West Regional Office. Sir Alasdair is a Clinical Pharmacologist and after training at the Royal Postgraduate Medical School, he was appointed to the Chair of Clinical Pharmacology at the University of Liverpool. Sir Alasdair was knighted in 2004.
Mental healthcare needs innovation. The traditional model of care delivery is often built around the needs of providers and payers not the preferences of patients and families. As a result, most people with mental illness avoid getting care. When they seek help, patients are likely to receive medications, psychosocial therapies, or devices but not an integrated plan that provides all the potential interventions in a personalized, evidence-based approach. The COMPASS medication-assisted psychotherapy strategy is innovative in that it integrates medication and psychotherapy. And it is disruptive by offering patients a treatment that many people prefer. I have chosen to be involved with COMPASS because I believe that this approach has potential but needs to be validated in rigorous, controlled clinical trials. My goal is to help COMPASS set a high bar for science so that, should the data be supportive, patients and families can trust that medication-assisted psychotherapy is an evidence-based approach.
I like working with smart people, and on interesting problems. Harnessing the potential of highly active psychotropic drugs for the treatment of depression lets me do both.
Professor Goodwin’s research interests are in the treatment of bipolar disorder and the application of neuroscience in understanding the neurobiology of mood disorders, with a focus on developing new treatments. He has been a lead investigator in clinical trials for bipolar affective disorder, including the BALANCE and CEQUEL studies. He works with industry in developing new models of psychotropic drug action in humans and has a growing interest in how we can harness technology to promote behaviour change and well being.
Professor Goodwin has served as a member of the Wellcome Trust Neurosciences Panel, the Council of the British Association for Psychopharmacology, the Clinical Fellowships Panel and Advisory Board of the MRC, and INSERM’s ANR panel. He was previously President of the British Association for Psychopharmacology and is a Fellow of the American College of Neuropsychopharmacology, Fellow and past President of the European College of Neuropsychopharmacology (ECNP) and a National Institute for Health Research (NIH) Senior Investigator.
COMPASS has provided the chance to use my experience to help to address a major mental health need combined with the challenge of testing a completely revolutionary approach to treatment. This is a rare opportunity and working with passionate and scientifically focussed people who are truly excited about the potential for an important medical breakthrough is both stimulating and a privilege.
Mike has been a member of the South Central England Research Ethics Committee since 2010. He previously Co- founded the UK Clinical Research Association (now Institute of Clinical research , ICR).
Mike has run multiple client Clinical Operations Management Consultancy over the last 9 years and is the founder of SintoPharm (Pharmaceutical Strategy into Operations) – a partnership consultancy with Pharma and other consultancy groups. SintoPharm has Clinical Operations Transformation Project experience with 5 of the top 10 Pharma Companies and smaller start up Companies.
In the next few years we will see significant breakthroughs in the treatment of many “silent” and debilitating mental health conditions, like depression, which affect millions of people around us. Having worked in this field for years, I am excited to help COMPASS on their pioneering mission to build and cross bridges that lead to a better future; one without prejudice or stigma, where empowered individuals have universal access to the best possible treatment and support.
Throughout his career he has been an outspoken advocate for change, innovation and entrepreneurship in healthcare, having co-authored articles, most notably “Beyond magic bullets: True Innovation in Healthcare” (Nature Reviews Drug Discovery, 2013), arguing for the need to develop holistic solution and new business models for patient suffering from serious mental illnesses. He also serves on various digital health advisory boards and engages in public speaking at prominent digital health conferences.
The focus on improving the treatment of depression, the rigorous scientific approaches being considered and the quality of the scientific team being formed were important elements in my consideration to join COMPASS, as was the strong commitment of the COMPASS leadership. In addition, the development and rigorous testing of the potential antidepressant effects of psilocybin, if successful, would be a scientific and therapeutic paradigm-changing contribution- opening new avenues to additional treatment innovations for other neuropsychiatric conditions.The opportunity to make this kind of contribution is a rare privilege.
His 45-year academic career has focused on the psychology and biology of mood disorders. His work has led to the development and evaluation of innovative treatments (medications, somatic treatments, psychotherapy), disease management protocols and clinical tools to improve early detection and care for persons with mood disorders and their families. As author of over 800 professional publications, and recipient of numerous awards. He was recognized as one of the “World’s Most Influential Scientific Minds” by Thomson Reuters i(2014).
I look forward to working for the benefit of people who are suffering in what I think will be a unique and creative endeavor.
Dr. Summergrad served as chief of Inpatient Psychiatric Services at Massachusetts General Hospital from 1987-1998 and as associate professor of psychiatry at Harvard Medical School. He served as staff to the Partners Mental Health Strategic Planning Committee of the Partners Board of Trustees in 1996-97 and as network director of the Partners Psychiatry & Mental Health System from 1997-2004. From 2000-2002 he served as the executive vice president for medical affairs and chief medical officer of the North Shore Medical Center where he oversaw quality, physician integration and the physician group while also serving as chief of psychiatry. He was a member of the Partners Healthcare System Executive Committee from 2000-2004. He served in 2013-14 as the chair of the American Hospital Association Governing Council for psychiatric and substance abuse services. In 1999 Dr. Summergrad chaired the Harvard University Provost’s Committee on Student Mental Services and currently co-chairs the Tufts University Mental Health Task Force with the President of Tufts University.
An international leader in medical psychiatric illness and care, Dr. Summergrad’s research focuses on mood disorders, medical-psychiatric illness, and health system design. He has published extensively with over 100 peer review publications, books, book chapters and other communications. He serves on the editorial boards of Academic Psychiatry, Current Psychiatry and Personalized Medicine in Psychiatry and guest edited a special issue of Academic Psychiatry on strategic planning in academic departments of psychiatry. A sought-after speaker, educator and consultant, he has served as a visiting professor and has given invited lectures throughout the United States and internationally. He is a member of the Diagnostic and Statistical Manual 5 Steering Committee of the American Psychiatric Association and the Standing Committee on Nominations of the World Psychiatric Association. He chaired the work group of the APA board of the role of psychiatry in health care reform which commissioned the Milliman report on the total health care costs associated with psychiatric illness. He is a distinguished fellow of the American Psychiatric Association, and a fellow of the American College of Psychiatrists and of the American College of Physicians and has received numerous other awards and honors including Castle and Connolly’s America’s Top Doctors from 2011 to the present. Most recently he received the Distinguished Faculty Award from Tufts University School of Medicine.
Dr. Summergrad earned his medical degree from the School of Medicine at the State University of New York at Buffalo in 1978 where he was elected to Alpha Omega Alpha in his junior year. He completed his training in internal medicine at Boston City Hospital and Boston University School of Medicine and in psychiatry at Massachusetts General Hospital and Harvard Medical School, where he was chief resident and a clinical fellow in psychiatry. He is board certified in both Psychiatry and Internal Medicine.